Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
You may also be interested in...
Ranbaxy-Teva Atorvastatin Mystery Deal Decoded: Many Likely Scenarios Aimed At “On Time” Launch
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan, one that could prove costly for Ranbaxy.
Ranbaxy-Teva Atorvastatin Mystery Deal Decoded: Many Likely Scenarios Aimed At “On Time” Launch
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan, one that could prove costly for Ranbaxy.
Ranbaxy Bags Atorvastatin Approval From U.S. FDA In A Nail-Biting Finish
U.S. FDA grants approval for the Lipitor generic to Ranbaxy at the last moment, and Ranbaxy announces a surprise deal with Teva, but mystery remains over a final settlement with FDA.